Showing results (251-260 of 742) with videos related to
Sort By:
Pageof 75
American Journal of Hematology|November 25, 2021
Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patientsPatrick W Mellors, Taxiarchis Kourelis, Ronald S Go, et al.Leukemia Research|February 27, 2009
Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology GroupMartha Q Lacy, Susanna Jacobus, Emily A Blood, et al.British Journal of Haematology|March 6, 2008
Anti-CD20 monoclonal antibody therapy in multiple myelomaPrashant Kapoor, Patricia T Greipp, William G Morice, et al.European Journal of Haematology|April 2, 2026
Efficacy of CD38-Targeted Therapy in Severe, Multi-Agent Refractory Immune Thrombocytopenia: A Case SeriesParth S Patel, Stefan Farrugia, Jordan Nunnelee, et al.European Journal of Haematology|May 28, 2024
Differences in the proteome within extracellular vesicles between premalignant and malignant plasma cell disordersPatrick M Vanderboom, Yogesh Chawla, Surendra Dasari, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 3, 2004
Fracture risk in monoclonal gammopathy of undetermined significanceL Joseph Melton, S Vincent Rajkumar, Sundeep Khosla, et al.Leukemia & Lymphoma|May 18, 2019
Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myelomaPatrick W Mellors, Moritz Binder, Francis K Buadi, et al.Blood|April 17, 2012
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trialShaji K Kumar, Suzanne R Hayman, Francis K Buadi, et al.Blood|April 12, 2012
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosisAngela Dispenzieri, Francis Buadi, Kristina Laumann, et al.American Journal of Hematology|June 2, 2011
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trialShaji K Kumar, Martha Q Lacy, Suzanne R Hayman, et al.Pageof 75